<DOC>
	<DOCNO>NCT00566345</DOCNO>
	<brief_summary>The primary purpose study demonstrate efficacy investigational Vero-cell derive influenza vaccine prevent infection adult population influenza virus antigenically similar one three strain vaccine . All subject randomize receive single 0.5 ml intramuscular injection one three lot seasonal Vero-cell derive influenza vaccine saline placebo . Subjects monitor 180 day follow vaccination occurrence adverse event . For determine antibody response , subject one blood draw one blood draw 21 day vaccination .</brief_summary>
	<brief_title>Efficacy Study Investigational Influenza Vaccine ( Vero Cell Derived ) Prevent Culture Confirmed Influenza Infection ( CCII )</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female subject 18 49 year age , inclusive , day screen understand study , agree provision give write informed consent prior study entry If female capable bearing child negative urine pregnancy test result within 24 hour vaccination Study Day 0 agree employ adequate birth control measure . For purpose study adequate birth control measure incorporate two type follow FDA approve birth control measure 60 day vaccination : hormonal type birth control ( implant , birth control pill , patch method ) intrauterine device , OR additional barrier type birth control measure ( i.e. , condom , diaphragm , cervical cap , etc. ) . Subjects risk factor complication influenza infection define Centers Disease Control Prevention ( CDC ) : pregnancy chronic disorder pulmonary cardiovascular system include asthma ( hypertension consider high risk condition ) chronic renal disorder chronic hepatic disorder chronic hematological disorder chronic metabolic disorder ( include diabetes mellitus ) immunosuppression ( include immunosuppression cause medication HIV ) condition compromise respiratory function handle respiratory secretion increase risk aspiration ( e.g. , cognitive dysfunction , spinal cord injury , seizure disorder neuromuscular disorder ) residence nursing home chronic care facility house person age chronic medical condition household contact child age 0 59 month someone include risk category list employment health care worker Subjects also exclude unable lead independent life result either physical mental handicap history severe allergic reaction anaphylaxis oral temperature &gt; = 99.5째 F ( 37.5째C ) day vaccination study . [ NOTE : Subjects meet exclusion criterion may reschedule vaccination study entry later date provide : 1 . ) oral temperature decrease &lt; 99.5째F ( 37.5째C ) reschedule date , 2 . ) inclusion/exclusion criterion meet , 3 . ) reschedule date 14 day past initial screening date , 4 . ) study site still enrol subject ] rash dermatologic condition tattoo may interfere injection site reaction rating receive blood transfusion immunoglobulin within 90 day study entry receive live vaccine within 4 week inactivate vaccine within 2 week study entry previously vaccinate influenza 2007/2008 northern hemisphere influenza season functional surgical asplenia know suspect problem alcohol drug abuse administer investigational drug within six week prior study entry concurrently participate clinical study include administration investigational product member team conduct study dependent relationship study investigator . Dependent relationship include close relative ( i.e. , child , spouse/partner , sibling , parent ) well employee investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>